Table 1

Participant demographic and clinical characteristics
HC (n = 23) BN (n = 21) HC vs BN
Age (in yrs) 27.3 ± 5.1 28.0 ± 7.1 NS
BMI (kg/m2) 21.3 ± 2.4 23.4 ± 5.0 NS
Hours since last meal 3.6 ± 2.8 5.5 ± 4.3 NS
Number on OC 8/23 (35%) 6/21 (29%) NS
Not on OC in follicular menstrual phase 9/15 (60%) 10/15 (67%) NS
Number on medication, compound and dose NA 9/21 (43%) NA
1 citalopram 20mg
1 citalopram 30 mg
3 fluoxetine 20 mg
1 fluoxetine 40 mg
2 fluoxetine 60 mg
1 venlafaxine 300 mg
Number of smokers 2/23 (9%) 3/21 (14%) NS
History of AN NA 8/21 (38%) NA
Duration of illness NA 0–5 year (n = 3) NA
5–10 year (n = 12)
10–15 year (n = 3)
>15 year (n = 3)
EDE-Q total 0.6 ± 0.5 4.8 ± 0.7 t(1,43) = 24.4; p < 0.01
EDE-Q restraint 0.4 ± 0.5 4.5 ± 0.9 t (1,43) = 18.7; p < 0.01
EDE-Q eating concerns 1.1 ± 0.3 4.2 ± 0.2 t (1,43) = 17.0; p < 0.01
EDE-Q weight concerns 0.7 ± 0.7 5.1 ± 0.8 t(1,43) = 19.8; p < 0.01
EDE-Q shape concerns 1.0 ± 0.8 5.3 ± 0.7 T(1,43) = 19.1; p < 0.01
DASS-21 total (range 0–86) 19.0 ± 6.5 74.4 ± 29.0 t(1,43) = 8.3; p < 0.01
DASS-depression (range 0–42) 5.4 ± 5.4 23.4 ± 11.6 t(1,43) = 6.7; p < 0.01
DASS-anxiety (range 0–42) 3.4 ± 4.0 23.2 ± 11.4 t(1,43) = 7.9; p < 0.01
DASS-stress (range 0–42) 11.2 ± 7.6 27.8 ± 9.6 t(1,43) = 6.4; p < 0.01
FCQ-Trait (range 39–236) 77.6 ± 17.3 159.4 ± 27.1 t(1,43) = 12.1; p < 0.01
FCQ-State (range 15–75) 25.4 ± 7.9 43.5 ± 12.3 t(1,43) = 5.9; p < 0.01
SAAS (range 0–80) 26.7 ± 8.4 64.3 ± 11.0 t(1,43) = 12.9; p < 0.01
PACS (range 0–25) 14.1 ± 3.6 21.3 ± 2.4 t(1,43) = 7.7; p < 0.01

BMI: body mass index; EDE-Q: Eating Disorder Examination–Questionnaire; DASS: depression, anxiety and stress scale; FCQ: food craving questionnaire; OC: oral contraceptive; AN: anorexia nervosa; NS; not significant; NA: not applicable; SSRI: selective serotonin reuptake inhibitor; SAAS: social anxiety appearance scale; PACS: physical appearance comparison scale.

Van den Eynde et al.

Van den Eynde et al. BMC Psychiatry 2013 13:302   doi:10.1186/1471-244X-13-302

Open Data